Published in Am J Epidemiol on March 28, 2007
Confounding control in healthcare database research: challenges and potential approaches. Med Care (2010) 3.01
Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution--a simulation study. Am J Epidemiol (2010) 2.74
Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Ann Intern Med (2008) 2.40
Adjustments for unmeasured confounders in pharmacoepidemiologic database studies using external information. Med Care (2007) 1.56
Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review. PLoS One (2013) 1.49
Developments in post-marketing comparative effectiveness research. Clin Pharmacol Ther (2007) 1.42
Propensity score-based sensitivity analysis method for uncontrolled confounding. Am J Epidemiol (2011) 1.09
Building useful evidence: changing the clinical research paradigm to account for comparative effectiveness research. J Comp Eff Res (2012) 1.01
Invited commentary: advancing propensity score methods in epidemiology. Am J Epidemiol (2007) 1.00
Confounding by dietary patterns of the inverse association between alcohol consumption and type 2 diabetes risk. Am J Epidemiol (2009) 1.00
Data for cancer comparative effectiveness research: past, present, and future potential. Cancer (2012) 0.89
Estimating Decision-Relevant Comparative Effects Using Instrumental Variables. Stat Biosci (2011) 0.88
Propensity score calibration in the absence of surrogacy. Am J Epidemiol (2012) 0.86
Clopidogrel and proton pump inhibitors--where do we stand in 2012? World J Gastroenterol (2012) 0.85
Analyzing partially missing confounder information in comparative effectiveness and safety research of therapeutics. Pharmacoepidemiol Drug Saf (2012) 0.85
Propensity Score Calibration and its Alternatives. Am J Epidemiol (2007) 0.80
Sensitivity analysis for causal inference using inverse probability weighting. Biom J (2011) 0.80
Validation sampling can reduce bias in health care database studies: an illustration using influenza vaccination effectiveness. J Clin Epidemiol (2013) 0.78
Prenatal triptan exposure and parent-reported early childhood neurodevelopmental outcomes: an application of propensity score calibration to adjust for unmeasured confounding by migraine severity. Pharmacoepidemiol Drug Saf (2015) 0.77
A General Framework for Considering Selection Bias in EHR-Based Studies: What Data Are Observed and Why? EGEMS (Wash DC) (2016) 0.76
Pharmacoepidemiology and "in silico" drug evaluation: is there common ground? J Clin Epidemiol (2008) 0.76
Prior event rate ratio adjustment for hidden confounding in observational studies of treatment effectiveness: a pairwise Cox likelihood approach. Stat Med (2016) 0.75
Incorporating linked healthcare claims to improve confounding control in a study of in-hospital medication use. Drug Saf (2015) 0.75
The ACCE method: an approach for obtaining quantitative or qualitative estimates of residual confounding. F1000Res (2014) 0.75
External adjustment of unmeasured confounders in a case-control study of benzodiazepine use and cancer risk. Br J Clin Pharmacol (2017) 0.75
Variable selection for propensity score models. Am J Epidemiol (2006) 10.68
Assessing the sensitivity of regression results to unmeasured confounders in observational studies. Biometrics (1998) 8.48
A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol (2005) 7.31
An introduction to instrumental variables for epidemiologists. Int J Epidemiol (2000) 6.17
Correction of logistic regression relative risk estimates and confidence intervals for systematic within-person measurement error. Stat Med (1989) 5.08
Smoking and lung cancer: recent evidence and a discussion of some questions. J Natl Cancer Inst (1959) 4.88
Correction of logistic regression relative risk estimates and confidence intervals for measurement error: the case of multiple covariates measured with error. Am J Epidemiol (1990) 4.80
Causal effects in clinical and epidemiological studies via potential outcomes: concepts and analytical approaches. Annu Rev Public Health (2000) 4.20
Basic methods for sensitivity analysis of biases. Int J Epidemiol (1996) 3.64
Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. Am J Epidemiol (2005) 3.33
Semi-automated sensitivity analysis to assess systematic errors in observational data. Epidemiology (2003) 3.30
Adjusting effect estimates for unmeasured confounding with validation data using propensity score calibration. Am J Epidemiol (2005) 2.55
Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction. Epidemiology (2005) 2.38
The performance of methods for correcting measurement error in case-control studies. Epidemiology (2002) 1.71
Bounding causal effects under uncontrolled confounding using counterfactuals. Epidemiology (2005) 1.67
Causation of bias: the episcope. Epidemiology (2001) 1.57
Sensitivity analysis for matched case-control studies. Biometrics (1991) 1.30
Corrections for exposure measurement error in logistic regression models with an application to nutritional data. Stat Med (1994) 1.13
Mortality of cystic fibrosis patients treated with tobramycin solution for inhalation. Epidemiology (2003) 1.13
Evaluation of regression calibration and SIMEX methods in logistic regression when one of the predictors is subject to additive measurement error. J Epidemiol Biostat (1999) 0.88
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 43.36
Variable selection for propensity score models. Am J Epidemiol (2006) 10.68
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet (2009) 10.52
A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol (2005) 8.77
Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.65
Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med (2005) 8.44
Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 8.32
High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology (2009) 7.40
A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol (2005) 7.31
Long-term persistence in use of statin therapy in elderly patients. JAMA (2002) 7.19
Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J (2004) 6.57
Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol (2005) 6.20
A randomized study of how physicians interpret research funding disclosures. N Engl J Med (2012) 5.47
Multivitamins in the prevention of cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA (2012) 5.25
Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 5.13
Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med (2014) 4.99
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol (2003) 4.95
Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. JAMA (2011) 4.73
Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol (2006) 4.70
Self-management education programs in chronic disease: a systematic review and methodological critique of the literature. Arch Intern Med (2004) 4.68
The rise and fall of epidemiology, 1950-2000 A.D. 1981. Int J Epidemiol (2007) 4.56
Full coverage for preventive medications after myocardial infarction. N Engl J Med (2011) 4.51
The comparative safety of analgesics in older adults with arthritis. Arch Intern Med (2010) 4.47
Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet (2012) 4.46
Multivitamins in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2012) 4.40
New FDA breakthrough-drug category--implications for patients. N Engl J Med (2014) 4.30
Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst (2002) 4.16
HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet (2010) 4.07
Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N Engl J Med (2002) 4.07
Depression and risk of sudden cardiac death and coronary heart disease in women: results from the Nurses' Health Study. J Am Coll Cardiol (2009) 3.99
A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol (2011) 3.98
Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA (2010) 3.85
Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol (2007) 3.82
The epidemiology of prescriptions abandoned at the pharmacy. Ann Intern Med (2010) 3.78
The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med (2006) 3.64
Burden of changes in pill appearance for patients receiving generic cardiovascular medications after myocardial infarction: cohort and nested case-control studies. Ann Intern Med (2014) 3.62
Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology (2006) 3.54
Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison. BMJ (2013) 3.43
The quality of pharmacologic care for vulnerable older patients. Ann Intern Med (2004) 3.34
Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. Am J Epidemiol (2005) 3.33
The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med (2011) 3.27
Rethinking the use of physicians as hired expert lecturers. Ann Intern Med (2014) 3.22
Blood pressure and risk of developing type 2 diabetes mellitus: the Women's Health Study. Eur Heart J (2007) 3.21
Drug-review deadlines and safety problems. N Engl J Med (2008) 3.16
Variations in pill appearance of antiepileptic drugs and the risk of nonadherence. JAMA Intern Med (2013) 3.13
Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation (2009) 3.09
Balancing innovation, access, and profits--market exclusivity for biologics. N Engl J Med (2009) 3.08
Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum (2006) 3.04
High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation (2013) 3.03
Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA (2011) 3.02
Confounding control in healthcare database research: challenges and potential approaches. Med Care (2010) 3.01
Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation (2004) 2.98
University-based science and biotechnology products: defining the boundaries of intellectual property. JAMA (2005) 2.95
Compliance with osteoporosis medications. Arch Intern Med (2005) 2.91
Noncompliance with antihypertensive medications: the impact of depressive symptoms and psychosocial factors. J Gen Intern Med (2002) 2.85
Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med (2002) 2.82
Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. J Clin Epidemiol (2006) 2.81
Internet marketing of herbal products. JAMA (2003) 2.77
Economic implications of evidence-based prescribing for hypertension: can better care cost less? JAMA (2004) 2.77
Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution--a simulation study. Am J Epidemiol (2010) 2.74
Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation (2003) 2.73
The comparative safety of opioids for nonmalignant pain in older adults. Arch Intern Med (2010) 2.71